The latest edition of Drug Safety Update from the MHRA reminds Healthcare Professionals that guidance on correct insertion of Nexplanon contraceptive implant has changed.
The change is intended to minimise the risk of neurovascular injury and migration of the implant from the insertion site. The new insertion site is located in an area overlying the triceps muscle, a location generally free of major blood vessels and nerves. Updated instructions have been added to the product information for Nexplanon and a letter has been sent to healthcare professionals. The Faculty of Sexual and Reproductive Healthcare (FSRH) has also issued a statement.